Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 | Latest News RSS feed

Sglt2 Inhibitors Market Current And Projected Size In Terms Of Volume And Value 20162024 - Latest News


SGLT2 Inhibitors Market Current and Projected size in terms of volume and value 2016-2024

SGLT2 inhibitors are expected to have high consumption in the near future due to simple treatment ... Dapaglifozin has no generic brands available in the market and is marketed by Boehringer Ingelheim ... read more

How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The emerging market continue to grow in mid teens and the size should double by 2018. Favorable Forces 1) R&D / New Drug Innovation 2) Austerity Measures to control costs 3) Emerging markets Growth Op... read more

Antidiabetic Drug Market by 2025: Top Players Like Eli Lilly, Oramed, Takeda, Novo Nordisk, Pfizer, Biocon

New York, NY -- (SBWIRE) -- 07/13/2018 -- Top key vendors in Antidiabetic Drug Market include are ... hard to find facts about the trends and innovation driving the current and future of Antidiabetic ... read more

Looking for another news?


Sirona Biochem Corporation-CEO's Report on Progress

We raised $600,000 in debt which gave us the financial runway to grow the value ... term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we ... read more


Inovalon Reports Fourth Quarter and Full Year 2016 Results

Feb. 22, 2017 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-base... read more

Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q3 2016 Results - Earnings Call Transcript

As you know sotagliflozin is a dual inhibitor of SGLT1 and SGLT2 for the treatment of diabetes ... Despite the sample size that achieved statistical significance with a P value of 0.01 compared to pla... read more

Merck Announces Second-Quarter 2017 Financial Results

“The company continues to invest in innovative science that addresses the critical needs of population health, which benefits patients while creating long-term value for shareholders ... an investigat... read more

Convertible visceral fat as a therapeutic target to curb obesity

Approved drugs that have browning properties as well as future drugs that target molecular pathways involved ... possibly because of their developmental route and the reduced size at which they die, t... read more

Eli Lilly's CEO Discusses Q1 2013 Results - Earnings Call Transcript

The biggest key is going to see how the pipeline plays out, and the future impact that has there, you would expect that in terms of ... also compare to current products on the market like Forteo. The ... read more

Pharmacotherapy for childhood obesity: present and future prospects

It is to be hoped that the future will bring new drugs targeting specific obesity ... ‘clinical trial’ or ‘review’ that was supplemented by manual searches for current and new drugs for adults (Table ... read more

Sirona Biochem Corporation-CEO's Report on Progress

We raised $600,000 in debt which gave us the financial runway to grow the value ... term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us